iPSC-Derived
Exosome Production Service

iPSC-derived exosomes are emerging as a highly scalable and customizable platform for next-generation extracellular vesicle therapies. iPSCs offer an ethically straightforward, readily sourced starting material that supports consistent large-scale manufacturing, advanced cargo engineering, and precise surface customization. 

Recent studies show that iPSC-derived exosomes deliver strong regenerative and anti-senescence effects across multiple tissues, including skin, eye, vascular, and musculoskeletal systems, often outperforming MSC-derived exosomes (Wang et al., 2020). With broad therapeutic potential and unmatched flexibility, iPSC-derived exosomes are rapidly becoming a leading candidate for innovative, cell-free regenerative medicine.

Find out more about iPSC-derived Exosomes:

▶ Understanding iPSC-derived Exosomes

▶ FAQ: iPSC Exosomes - Preclinical Research Overview

iPSC-Derived Exosome Manufacturing Services for Preclinical Research

Why Choose REPROCELL Japan GMP Manufacturing Facility?

iPSC-derived exosome manufacturing takes place at REPROCELL’s GMP facility in Tonomachi, Japan. The center operates under Japan’s Act on the Safety of Regenerative Medicine and maintains a certified quality management system for clinical-grade cell product manufacturing. Production takes place in rigorously controlled cleanroom environments featuring monitored air quality, aseptic processing, and strict environmental oversight. With experience supporting advanced cell-based products, including StemRNA Clinical iPSC Clones and TIL (Tumor-Infiltrating Lymphocytes) for clinical research, the facility provides a reliable foundation for producing high-quality iPSC-derived exosomes for research and clinical development.

Let’s collaborate:

Discover how we can take your exosome and vesicle programmes from development to GMP manufacturing with Japanese quality and global regulatory readiness. Contact us via the inquiry form.